<DOC>
	<DOC>NCT00166816</DOC>
	<brief_summary>The purpose of this study is to understand the pharmacokinetic of sirolimus in different regimens, as well as the dose-level relationship of cyclosporine and tacrolimus, and design the most appropriate cyclosporine/sirolimus/steroid or tacrolimus/sirolimus/steroid dose regimen for Taiwanese.</brief_summary>
	<brief_title>The Pharmacokinetics of Sirolimus When Combined With Cyclosporine or Tacrolimus in Renal Transplant Patients</brief_title>
	<detailed_description>The dose and pharmacokinetic of an immunosuppressant may differ in different ethnics, and different combinations. The purpose of this study is to determine the dose-level relationship of sirolimus through pharmacokinetic study. The dose-level relationship of cyclosporine and tacrolimus was also assessed. From clinical outcome and blood level of sirolimus and cyclosporine or tacrolimus, we can design the most appropriate cyclosporine/sirolimus/steroid or tacrolimus/sirolimus/steroid dose regimen for Taiwanese.</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>De novo kidney transplantation patients, aged 13－65 years,have aminotransferase concentrations within 2 times the upper limit of normal. pregnancy, tuberculosis, hepatitis B or C carrier status, human immunodeficiency virus－positive status, retransplantation or multiorgan transplantation, or history of rheumatoid arthritis.</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2001</verification_date>
	<keyword>Sirolimus</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Cyclosporine</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Immunosuppressive Agents</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Kidney Transplantation</keyword>
	<keyword>Transplantation</keyword>
</DOC>